Identification
- Summary
Pyrophosphoric acid is an ingredient of a radiopharmaceutical used to visualize bone abnormalities and cardiovascular abnormalities and also used as an ingredient in some products to prevent iron deficiency anemia.
- Generic Name
- Pyrophosphoric acid
- DrugBank Accession Number
- DB04160
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
Structure for Pyrophosphoric acid (DB04160)
- Weight
- Average: 177.9751
Monoisotopic: 177.943225506 - Chemical Formula
- H4O7P2
- Synonyms
- acide diphosphorique
- Diphosphoric acid
- Diphosphorsäure
- Pyrophosphorsäure
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination as diagnostic agent Gastrointestinal bleeding Combination Product in combination with: Stannous chloride (DB11056) •••••••••••• Prevention of Iron deficiency anemia caused by hemodialysis-dependent chronic kidney disease (hdd-ckd) •••••••••••• Used in combination as diagnostic agent Myocardial infarction Combination Product in combination with: Stannous chloride (DB11056) •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UFarnesyl diphosphate synthase modulatorEscherichia coli (strain K12) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium acetate Calcium acetate can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium carbonate Calcium carbonate can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium chloride Calcium chloride can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium citrate Calcium citrate can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sodium pyrophosphate O352864B8Z 7722-88-5 FQENQNTWSFEDLI-UHFFFAOYSA-J Sodium pyrophosphate decahydrate IY3DKB96QW 13472-36-1 VZWGHDYJGOMEKT-UHFFFAOYSA-J - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Pyrophosphate Injection, powder, lyophilized, for solution 27.6 mg/1 Intravenous Anazao Health Corporation 2012-05-23 Not applicable US 
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image V34 Colour Corrector Cream 0.5 g/100mL Topical LLRN PERSONAL CARE(SHENZHEN)CO., LTD 2023-11-23 Not applicable US V34 Colour Corrector Cream 0.5 g/100mL Topical Nanchang Dental Bright Technology Co.,Ltd. 2023-10-30 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Dr. DADDYS GumToothpaste Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (17 g/100g) + Sodium fluorophosphate (0.76 g/100g) + alpha-Tocopherol acetate (0.2 g/100g) Paste, dentifrice Dental TB Healthcare Co., Ltd. 2021-11-06 Not applicable US Dr. DADDYS GumToothpaste Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (17 g/100g) + Sodium fluorophosphate (0.76 g/100g) + alpha-Tocopherol acetate (0.2 g/100g) Paste, dentifrice Dental TB Healthcare Co., Ltd. 2021-11-06 Not applicable US Dr. DADDYS Junior Toothpaste(Green grape) Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (15 g/100g) + Sodium fluorophosphate (0.758 g/100g) Paste, dentifrice Dental TB Healthcare Co., Ltd. 2022-02-26 Not applicable US Dr. DADDYS Kids Tooth Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (13 g/100g) + Sodium fluorophosphate (0.36 g/100g) Paste, dentifrice Dental TB Healthcare Co., Ltd. 2021-01-01 Not applicable US Dr. DADDYS Kids Toothpaste(Raspberry flavor) Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) + Sodium fluorophosphate (0.36 g/100g) Paste, dentifrice Dental TB Healthcare Co., Ltd. 2021-09-20 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Dr. DADDYS GumToothpaste Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (17 g/100g) + Sodium fluorophosphate (0.76 g/100g) + alpha-Tocopherol acetate (0.2 g/100g) Paste, dentifrice Dental TB Healthcare Co., Ltd. 2021-11-06 Not applicable US Dr. DADDYS GumToothpaste Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (17 g/100g) + Sodium fluorophosphate (0.76 g/100g) + alpha-Tocopherol acetate (0.2 g/100g) Paste, dentifrice Dental TB Healthcare Co., Ltd. 2021-11-06 Not applicable US Dr. DADDYS Junior Toothpaste(Green grape) Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (15 g/100g) + Sodium fluorophosphate (0.758 g/100g) Paste, dentifrice Dental TB Healthcare Co., Ltd. 2022-02-26 Not applicable US Dr. DADDYS Kids Tooth Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (13 g/100g) + Sodium fluorophosphate (0.36 g/100g) Paste, dentifrice Dental TB Healthcare Co., Ltd. 2021-01-01 Not applicable US Dr. DADDYS Kids Toothpaste(Raspberry flavor) Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) + Sodium fluorophosphate (0.36 g/100g) Paste, dentifrice Dental TB Healthcare Co., Ltd. 2021-09-20 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as non-metal pyrophosphates. These are inorganic non-metallic compounds containing a pyrophosphate as its largest oxoanion.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous non-metal compounds
- Class
- Non-metal oxoanionic compounds
- Sub Class
- Non-metal pyrophosphates
- Direct Parent
- Non-metal pyrophosphates
- Alternative Parents
- Inorganic oxides
- Substituents
- Inorganic oxide / Non-metal pyrophosphate
- Molecular Framework
- Not Available
- External Descriptors
- phosphorus oxoacid, acyclic phosphorus acid anhydride (CHEBI:29888)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4E862E7GRQ
- CAS number
- 2466-09-3
- InChI Key
- XPPKVPWEQAFLFU-UHFFFAOYSA-N
- InChI
- InChI=1S/H4O7P2/c1-8(2,3)7-9(4,5)6/h(H2,1,2,3)(H2,4,5,6)
- IUPAC Name
- (phosphonooxy)phosphonic acid
- SMILES
- OP(O)(=O)OP(O)(O)=O
References
- Synthesis Reference
Kiyoshi Nakayama, Hiroshi Hagino, "Method for preparing cytidine diphosphate choline." U.S. Patent USRE0288861, issued August 15, 1972.
USRE0288861- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000250
- KEGG Compound
- C00013
- PubChem Compound
- 1023
- PubChem Substance
- 46507760
- ChemSpider
- 996
- BindingDB
- 50147591
- 1546425
- ChEBI
- 29888
- ChEMBL
- CHEMBL1160571
- ZINC
- ZINC000006827695
- PDBe Ligand
- PPV
- Wikipedia
- Pyrophosphoric_acid
- PDB Entries
- 1xsp / 2bcq / 2bcr / 2bcs / 2bcu / 2e90 / 2e9t / 2e9z / 2ec0 / 2o1c … show 162 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Recruiting Diagnostic Amyloidosis; Systemic 1 Not Available Completed Treatment Tooth Bleaching 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Paste, dentifrice Topical Paste Topical Paste, dentifrice Dental Paste, dentifrice Oral Paste Dental Injection, powder, lyophilized, for solution Intravenous Injection, powder, lyophilized, for solution Intravenous 27.6 mg/1 Injection, powder, for solution Intravenous Injection, powder, for solution Intravenous 20 mg/Vial Cream Topical 0.5 g/100mL Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 61 °C PhysProp - Predicted Properties
Property Value Source logP -1.4 Chemaxon pKa (Strongest Acidic) 1.7 Chemaxon Physiological Charge -3 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 124.29 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 25.52 m3·mol-1 Chemaxon Polarizability 10.28 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.7458 Blood Brain Barrier + 0.9868 Caco-2 permeable - 0.6915 P-glycoprotein substrate Non-substrate 0.8723 P-glycoprotein inhibitor I Non-inhibitor 0.9435 P-glycoprotein inhibitor II Non-inhibitor 0.9596 Renal organic cation transporter Non-inhibitor 0.9497 CYP450 2C9 substrate Non-substrate 0.8692 CYP450 2D6 substrate Non-substrate 0.8528 CYP450 3A4 substrate Non-substrate 0.7126 CYP450 1A2 substrate Non-inhibitor 0.8947 CYP450 2C9 inhibitor Non-inhibitor 0.8759 CYP450 2D6 inhibitor Non-inhibitor 0.9335 CYP450 2C19 inhibitor Non-inhibitor 0.8574 CYP450 3A4 inhibitor Non-inhibitor 0.9413 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9653 Ames test Non AMES toxic 0.828 Carcinogenicity Carcinogens 0.6317 Biodegradation Ready biodegradable 0.835 Rat acute toxicity 2.9431 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8422 hERG inhibition (predictor II) Non-inhibitor 0.973
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 129.6906349 predictedDarkChem Lite v0.1.0 [M-H]- 88.55534 predictedDeepCCS 1.0 (2019) [M+H]+ 92.04569 predictedDeepCCS 1.0 (2019) [M+Na]+ 100.58165 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Unknown
- Actions
- Modulator
- General Function
- Metal ion binding
- Specific Function
- Not Available
- Gene Name
- ispA
- Uniprot ID
- P22939
- Uniprot Name
- Farnesyl diphosphate synthase
- Molecular Weight
- 32159.22 Da
References
- Sun S, McKenna CE: Farnesyl pyrophosphate synthase modulators: a patent review (2006 - 2010). Expert Opin Ther Pat. 2011 Sep;21(9):1433-51. doi: 10.1517/13543776.2011.593511. Epub 2011 Jun 25. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:31